Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
New Year’s SALE: Up to 40% OFF InvestingPro+ CLAIM OFFER
Gavi rejects Novavax's claim on COVID vaccine deal breach
© Reuters. FILE PHOTO: Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Novavax logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/Illustration
(Reuters) -Global vaccine alliance Gavi on Tuesday rejected Novavax (NASDAQ:NVAX)'s claim that the group had breached an advance purchase agreement to procure 350 million doses of the company's COVID-19 vaccine.
Novavax said on Monday that it had issued a notice to Gavi for terminating the agreement with immediate effect, citing the alliance's failure to procure the doses it had agreed to buy in May last year for the COVAX facility, a global vaccine distribution program.
The company's shares were down 12% in afternoon trade.
"It is clear that Novavax will not be able to meet its commitment to manufacture" the doses under the agreement for COVAX before the end of 2022, a Gavi spokesperson told Reuters.
More than 18 months after signing the agreement, Novavax has not been able to make a single dose available to COVAX from the contractually stipulated sites to-date, Gavi said.
Novavax received a non-refundable advance payment of $350 million from Gavi last year and an additional $350 million this year after the vaccine got the World Health Organization's emergency use listing.
Gavi said that it reserved all rights, including recovery of advance payments to the company.
"We think a legal battle will ensue and that this will ultimately get determined by the lawyers," said CFRA analyst Stewart Glickman.
In response to Gavi's statement, Novavax reiterated that it has been ready to meet its commitment to manufacture and deliver doses for the COVAX facility.
Novavax also has a pact with Serum Institute of India for manufacturing a version of the vaccine under the brand Covovax, which would also be supplied to the COVAX facility.
Gavi's spokesperson said Serum Institute had a 300 million dose commitment for Covovax, with options for 750 million more doses if needed.
A Serum Institute spokesperson declined to comment.
Novavax recently cut its full-year forecast yet again, hurt by late authorizations of its COVID vaccine globally amid a waning demand for shots.
Related Articles
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.